MX2021011823A - Derivado pirroloheterociclico, metodo de preparacion del mismo y su aplicacion en medicina. - Google Patents

Derivado pirroloheterociclico, metodo de preparacion del mismo y su aplicacion en medicina.

Info

Publication number
MX2021011823A
MX2021011823A MX2021011823A MX2021011823A MX2021011823A MX 2021011823 A MX2021011823 A MX 2021011823A MX 2021011823 A MX2021011823 A MX 2021011823A MX 2021011823 A MX2021011823 A MX 2021011823A MX 2021011823 A MX2021011823 A MX 2021011823A
Authority
MX
Mexico
Prior art keywords
derivative
pyrroloheterocyclic
preparation
method therefor
medicine
Prior art date
Application number
MX2021011823A
Other languages
English (en)
Inventor
Fang Yang
Feng He
Weikang Tao
Xin Li
Guodong Cai
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2021011823A publication Critical patent/MX2021011823A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La presente solicitud proporciona un derivado pirroloheterocíclico, un método de preparación del mismo y una aplicación del mismo en medicina. Específicamente, la presente solicitud proporciona un novedoso derivado pirroloheterocíclico representado por la fórmula (I), un método de preparación del mismo, una composición farmacéutica que comprende el derivado, y una aplicación del derivado como agente terapéutico, particularmente como inhibidor de ERK, donde los sustituyentes en la fórmula tienen las mismas definiciones que las de la descripción. (ver Fórmula).
MX2021011823A 2019-03-29 2020-03-27 Derivado pirroloheterociclico, metodo de preparacion del mismo y su aplicacion en medicina. MX2021011823A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910247297 2019-03-29
CN202010194720 2020-03-19
PCT/CN2020/081591 WO2020200069A1 (zh) 2019-03-29 2020-03-27 吡咯并杂环类衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
MX2021011823A true MX2021011823A (es) 2021-10-22

Family

ID=72664469

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011823A MX2021011823A (es) 2019-03-29 2020-03-27 Derivado pirroloheterociclico, metodo de preparacion del mismo y su aplicacion en medicina.

Country Status (11)

Country Link
US (1) US20220185818A1 (es)
EP (1) EP3950690A4 (es)
JP (1) JP2022528083A (es)
KR (1) KR20210146956A (es)
CN (1) CN113544131B (es)
AU (1) AU2020251621A1 (es)
BR (1) BR112021018924A2 (es)
CA (1) CA3135070A1 (es)
MX (1) MX2021011823A (es)
TW (1) TW202102505A (es)
WO (1) WO2020200069A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4071155A4 (en) 2019-12-06 2024-01-17 D3 Bio Wuxi Co Ltd THIAZOLOLACTAM COMPOUND USED AS ERK INHIBITOR AND USE THEREOF
CN114315837B (zh) * 2020-09-29 2023-06-16 江苏恒瑞医药股份有限公司 一种erk抑制剂的结晶形式及其制备方法
JP2023543080A (ja) * 2020-09-29 2023-10-12 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 ピロロ複素環系誘導体の結晶及びその製造方法
TWI809904B (zh) * 2021-06-02 2023-07-21 大陸商南京明德新藥研發有限公司 一種二甲基取代的噻唑並吡咯酮類化合物的晶型及其製備方法
WO2022268065A1 (en) * 2021-06-22 2022-12-29 Fochon Biosciences, Ltd. Compounds as erk inhibitors
WO2023185869A1 (zh) * 2022-03-28 2023-10-05 江苏恒瑞医药股份有限公司 一种吡咯并杂环类衍生物的富马酸盐的晶型及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2333157A1 (en) 1998-05-26 1999-12-02 Smithkline Beecham Corporation Novel substituted imidazole compounds
EP1207864A2 (en) 2000-02-05 2002-05-29 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of erk
AU782878B2 (en) 2000-02-05 2005-09-08 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
BR0104424A (pt) 2000-02-05 2002-01-08 Vertex Pharma Composições de pirazol úteis como inibidores de erk
EP1317450B1 (en) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2012118850A1 (en) 2011-02-28 2012-09-07 Array Biopharma Inc. Serine/threonine kinase inhibitors
JP2013010719A (ja) * 2011-06-30 2013-01-17 Dainippon Sumitomo Pharma Co Ltd ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
JP5792128B2 (ja) 2011-07-29 2015-10-07 富士フイルム株式会社 １，５−ナフチリジン誘導体又はその塩
TW201348226A (zh) * 2012-02-28 2013-12-01 Amgen Inc 作為ｐｉｍ抑制劑之醯胺
WO2014179154A2 (en) 2013-04-30 2014-11-06 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
MX370906B (es) 2013-12-30 2020-01-09 Genentech Inc Inhibidores de serina/treonina cinasa.
TWI704151B (zh) * 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
CN107849046B (zh) * 2015-06-03 2020-06-12 常州捷凯医药科技有限公司 作为erk抑制剂的杂环化合物
CA2986587C (en) * 2015-06-15 2024-03-12 Asana Biosciences, Llc Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer
WO2017180817A1 (en) 2016-04-15 2017-10-19 Musc Foundation For Research Development Treatment of septicemia and ards with erk inhibitors
CA3036079A1 (en) 2016-09-08 2018-03-15 Sabila Biosciences Llc 1,2-dithiolane compounds useful in neuroprotection, autoimmune and cancer diseases and conditions

Also Published As

Publication number Publication date
EP3950690A1 (en) 2022-02-09
CN113544131A (zh) 2021-10-22
CA3135070A1 (en) 2020-10-08
WO2020200069A1 (zh) 2020-10-08
AU2020251621A1 (en) 2021-11-04
JP2022528083A (ja) 2022-06-08
BR112021018924A2 (pt) 2022-02-01
EP3950690A4 (en) 2022-12-07
TW202102505A (zh) 2021-01-16
US20220185818A1 (en) 2022-06-16
KR20210146956A (ko) 2021-12-06
CN113544131B (zh) 2024-03-15

Similar Documents

Publication Publication Date Title
MX2021011823A (es) Derivado pirroloheterociclico, metodo de preparacion del mismo y su aplicacion en medicina.
MY192084A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
MX2021003655A (es) Derivado de indol macrociclico, metodo de preparacion del mismo y aplicacion del mismo en medicina.
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
GEP20125511B (en) Mapk/erk kinase inhibitors
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
GEP20156330B (en) Aryl-and heteroarylcarbonyl derivatives of hexahydro- indenopyridine and octahydrobenzoquinoline
ZA202110357B (en) Inhibitor containing bicyclic derivative, preparation method therefor and use thereof
MX2020013785A (es) Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo.
EA201000436A1 (ru) Стероидные [3,2-с]пиразольные соединения, обладающие глюкокортикоидной активностью
MX2022014007A (es) Compuestos como inhibidores de bcl-2.
NZ592429A (en) PHENANTHROINDOLIZIDINE DERIVATIVE AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
WO2021011713A8 (en) Imidazopyrimidines as eed inhibitors and the use thereof
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
ZA202206481B (en) Amide derivative and preparation method therefore and use thereof in medicine
MX2021014680A (es) Derivado de benzotriazol.
NZ592392A (en) PHENANTHROINDOLIZIDINE COMPOUND AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
MX2019008181A (es) Inhibidores selectivos hdac6, metodos de preparacion y aplicacion de los mismos.
MX2023000868A (es) Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo.
PH12021550439A1 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
PH12021550788A1 (en) New amino-pyrimidonyl-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them